logo
Plus   Neg
Share
Email

Pfizer's Phase 3 Study Of Abrocitinib Shows Positive Top-Line Results

Pfizer Inc. (PFE) announced Wednesday positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD). The study also achieved all co-primary and secondary endpoints.

The study was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12 weeks.

Top-line results showed that by week 12 the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was statistically significantly higher than placebo.

In addition, the results demonstrate response to treatment for a statistically significant number of patients during the first two to four weeks following first dose.

These top-line findings are encouraging and provide evidence that abrocitinib, if approved, could be an effective new oral once-daily treatment option for patients.

Abrocitinib received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate to severe AD in February 2018.

If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.

AD is a chronic skin disease characterized by inflammation of the skin and skin barrier defects. AD is one of the most common, chronic, relapsing childhood dermatoses, affecting 1% to 3% of adults and 15% to 20% of children worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A survey has shown that while a majority of Americans want to buy a car that contributes substantially to the U.S. economy amid rising trade tensions, most of the "American-made" cars are actually produced by foreign automakers. According to Cars.com's 2019 American-Made Index, the most 'American-made' vehicle in 2019 is the Jeep Cherokee. Streaming giant Netflix Inc. (NFXL) is set to lose the right to stream "The Office," one of the most popular TV show on the service. NBC Universal announced it is taking back the popular TV show for its own streaming platform, beginning January 2021. "We're sad that NBC has decided to take The... Chinese smartphone maker Xiaomi has announced that its recently launched Mi Band 4 crossed 1 million units sales in just eight days. Xiaomi's Director of Product Management Donovan Sung tweeted this news as he thanked Mi fans for the achievement. "Sharing some great news with our global Mi Fans....
Follow RTT